AstraZeneca PLC (AZN)vsOwlet Inc (OWLT)
AZN
AstraZeneca PLC
$185.95
+0.86%
HEALTHCARE · Cap: $282.69B
OWLT
Owlet Inc
$5.11
+3.23%
HEALTHCARE · Cap: $145.01M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 56353% more annual revenue ($60.44B vs $107.06M). AZN leads profitability with a 17.2% profit margin vs -43.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
OWLT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.1%
Fair Value
$194.57
Current Price
$185.95
$8.62 discount
Intrinsic value data unavailable for OWLT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -526.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : OWLT
OWLT has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while OWLT is a turnaround play — different risk/reward profiles.
OWLT carries more volatility with a beta of 1.86 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a pioneering leader in infant health technology, focused on enhancing the safety and wellness of newborns through its innovative monitoring solutions. Its flagship product, the Owlet Smart Sock, utilizes advanced pulse oximetry to deliver real-time insights into heart rates and oxygen levels, allowing parents to access crucial health data via mobile devices. As demand for pediatric health monitoring continues to rise, Owlet is strategically positioned to expand its product portfolio and strengthen its market presence. The company's commitment to delivering actionable health information and improving pediatric care aligns closely with institutional investors' interests in the rapidly evolving landscape of health technology.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?